Arie Belldegrun MD FACS - Chairman
Arie Belldegrun, M.D., FACS, has served as our Chairman since December 2012. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/National Institute of Health, as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Belldegrun has more than 20 years of experience in the life science and biotech industry and has been closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson & Johnson. He currently serves as Chairman and Chief Executive Officer of Kite Pharma, Inc. (NASDAQ: KITE), Chairman of Arno Therapeutics, Inc. (OTCQB: ARNI), and Two River Group, and as a board member of and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, Israel, his post graduate studies in Immunology at the Weizmann Institute of Science, Israel, and his residency in Urologic Surgery at Harvard Medical School. Dr. Belldegrun has authored several books in Oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. Dr. Belldegrun is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons (AAGUS).
Stuart Holden MD - Board Member
Stuart Holden, M.D., has served as our director since December 2015. Dr. Holden has been the Chairman of ProQuest Investments’ Scientific Advisory Board since its founding. Since May 2014 Dr. Holdern is a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked on the frontlines of prostate cancer for more than 36 years and has pioneered new treatments for urologic cancers. Dr. Holden’s dedication to patient care resulted in him being named medical director of the Prostate Cancer Foundation, which is the world’s largest prostate cancer research funding organization; he has held this position since the foundation’s inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.A. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital – Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society.
Chaim Hurvitz - Board Member
Chaim I. Hurvitz has served as our director since May 2013. Mr. Hurvitz has 31 years of experience in the life science inducstry. Mr. Hurvitz has been a director of Teva since October 2010. Mr. Hurvitz currently serves as CEO of CHealth, a private venture capital firm, a position he has held since May 2011. Previously, Mr. Hurvitz was a member of the senior management of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), serving as the President of Teva International Group from 2002 until 2010, as President and Chief Executive Officer of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice President Israeli Pharmaceutical Sales from 1999 until 2002. Mr. Hurvitz presently serves as a director of Aposense Ltd. (TASE: APOS). Mr. Hurvitz received a B.A. in Political Science and Economics from Tel Aviv University, Israel.
Ran Nussbaum - Board Member
Ran is a managing partner and co-founder of The Pontifax Group. The fund is running more than 45 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member on many of Pontifax’s portfolio companies, including Kite pharma, Keros (as chairman), cCAM Biotherapeutics ,Eloxx, Nutrinia, Quiet Therapeutics and other bio-pharma companies. He also chaired OCON Medical, NasVax and ran Biomedix and Spearhead in the past.
Pini Orbach PhD - Board Member
Pini Orbach, Ph.D., has served as our director since October 2014. Dr. Orbach has 10 years of experience in executive positions. As of February 2010 Dr. Orbach is the head of Pharma and Life Science at Arkin Holdings. Dr. Orbach is the Chief Executive Officer of NanoDoc Technology, Inc., and a board member at HealOr Ltd. Prior to joining Arkin Holdings, Dr. Orbach served as Chief Executive Officer of several Health Care companies in Israel and abroad. Dr. Orbach serves as Director at Metallo-Therapy Ltd., Chairman of the Board of cCAM Biotherapeutics Ltd. He also serves as a Director of FusiMab Ltd., and Quiet Therapeutics Ltd. He received his Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School.
Ron Bentsur - Board Member and CEO
Ron Bentsur has served as our Chief Executive Officer as of August 2015 and as a director as of October 2015. Ron Bentsur has more than 15 years of experience in the biotech industry. Until 2015 Mr. Bentsur served for more than five years as the Chief Executive Officer Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia™ (ferric citrate). Prior to that Mr. Bentsur served as CEO of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000-2006, serving as the Keryx’s Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA (Magna Cum Laude), from New York University’s Stern Graduate School of Business.
Kate Falberg - Board Member
Kate Falberg has served as our director since April 2017. Ms. Falberg has held several CFO and Head of Strategy and Corporate Development roles in the technology and biotechnology industries including for Applied Magnetics, Amgen and, most recently, Jazz Pharmaceuticals. She also currently serves on the boards of, Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, BioMarin Pharmaceutical and The Trade Desk, and formerly served on multiple boards including Medivation and Halozyme Therapeutics. Ms. Falberg holds a B.A. and M.B.A from UCLA, is a CPA, inactive, and a UCLA Certified Director.